Top 5 Animal Health Companies’ R&D Pipelines (2026–2031) – Disproportionate Growth is in Future

While short term investors are looking forward to Q2′ 2026 numbers from leading animal health companies – this market research attempts to present a long-term analysis of Top 5 animal health companies by rigorously evaluating respective R&D pipelines of these companies.

This analysis focuses on the Top 5 AH companies which are most likely to create disproportionate shareholder value through pipeline innovations and potential estimated values from those innovations. This research is based on press rleases, investor call transcripts and publically available information on the respective pipelines of these Top 5 Animal Health companies. These Top 5 AH covered in this research are:

1. Zoetis

2. MSD Animal Health

3. Elanco Animal Health

4. Boehringer Ingelheim Animal Health

5. IDEXX Laboratories

The animal health industry currently has 4 mega-themes driving pipeline value s reflected in recent revenues of these 5 companies:

• Monoclonal antibodies (mAbs)

• Long-acting parasiticides

• AI-enabled diagnostics and precision medicine

• DIVA/mRNA Vaccines and Methane gas management product/s for Livestock

While the first 3 mega-themes are focused on Companion Animals, last mega theme plays out in rather not-so glamorous Livestock segment.

1. Zoetis — Deepest Innovation Pipeline

Current Blockbusters

• Librela

• Solensia

• Simparica Trio

Industry consensus still views Zoetis as the leader in veterinary biologics and companion-animal innovation. Librela and Solensia effectively created the anti-NGF category in veterinary medicine.

Pipeline Projects

Strategic Assessment

Zoetis has moved beyond traditional pharmaceuticals toward a biologics company. The company’s most valuable future platform is likely monoclonal antibodies rather than parasiticides.

Probability of New $1B Franchise – Very High

2. MSD Animal Health (Merck)

Current Growth Engines

• Bravecto

• BRAVECTO QUANTUM and very recently approved,

• Numelvi

BRAVECTO QUANTUM is the most disruptive recent launch in animal health because it converts monthly dosing into annual dosing. FDA approval came in 2025 and label expansions followed in 2026. As rollouts of Bravecto Quantum continue, the true revenue gains will be visible from End-2026 / 2027 onwards.

Pipeline Projects

Strategic Assessment

MSD’s strongest asset is not a molecule but a platform: long-duration veterinary medicines, specifically parasiticides. The company is likely to dominate annual injectable parasite protection for time to come as available information doesn’t throw up competition anytime soon.

Probability of New $1B Franchise – Very High

3. Elanco

Highest Upside Relative to Valuation – Elanco is your typical turn around story which has pivoted very successfully and impressively to Companion Animals segment from being a largely Livestock focused company with medicated feed additives such as Rumensin as key brands.

Recently concluded Investor Day disclosures indicate more than 10 major innovation projects with blockbuster potential and aggregate peak sales opportunities exceeding $1.5 billion. The company expects 5-6 significant approvals between 2026 and 2031.

Existing INNOVATION Launches

• Zenrelia

• Credelio Quattro

• Bovaer

Credelio Quattro became Elanco’s fastest pet-health blockbuster and crossed $100 million sales rapidly after launch.

Pipeline Projects

Strategic Assessment

Elanco has quietly assembled one of the industry’s most attractive late-stage pipelines and now possesses internal monoclonal antibody and immunotherapy capabilities.

Probability of New $1B Franchise – High

4. Boehringer Ingelheim Animal Health

While BIAH is out and out Vaccines and Parasiticides Specialist what with very successful portfolio of swine vaccines, poultry vaccines and Afoxalaner (NEXGARD Brand Family) – truly the first, oral broad spectrum endectocide in the world. Hoiwever, BIAH has so  far failed to capitalize on its “once leadership” in Laners / parasiticides segment.

Existing Franchises

• NexGard

• NexGard Plus

• Ingelvac Vaccines

NexGard Plus remains one of the strongest broad-spectrum companion-animal products globally and expectations are very high that BIAH soon commercializes either a new parasiticide or unique life-cycle management for Nexgard Family.

Pipeline Projects

Boehringer’s VAXXITEK avian influenza platform may become increasingly important as countries move toward vaccination-based HPAI control programs. The company remains the strongest vaccine innovator in livestock health. Current analysis DOES NOT CAPTURE any upsides yet from BIAH’s acquisition of Saiba Animal Health which has a pipeline of VLP-Vaccines, which if successfully developed and approved by regulatory authorities, have the potential to change future of animal vaccines and disease management in the global animal health industry.

Probability of New $1B Franchise – Moderate

5. IDEXX Laboratories

Most Disruptive Diagnostics Pipeline

Unlike pharmaceutical competitors on this list, IDEXX’s value creation comes from diagnostics and software and not from new drugs and molecules.

Core, Existing Growth Platforms

• Digital Cytology

• AI-assisted diagnostics

• Oncology diagnostics

• Molecular diagnostics

• Cloud-connected veterinary workflows

Pipeline Projects

Management continues to identify InVueDx, CancerDx and expanded Catalyst menus as major innovation drivers. While Idexx has a few competitors’ but major risk to Idexx seems only from emergy AI Diagnostic start ups and not so much from entrenched incumbents.

Strategic Assessment

IDEXX may ultimately capture the highest-margin economics in animal health because diagnostics create recurring consumable revenue and software lock-ins potentially locking out competition.

Probability of New $1B Franchise – Moderate to High

Most Important Assets Across Animal Health (2026–2031)

2030 Industry Outlook

The next decade’s winners are unlikely to be traditional antibiotics or acute therapy products or vaccines alone. The highest-value areas are likely to be:

1. Monoclonal antibodies (Zoetis, Elanco)

2. Long-acting injectables (MSD alone so far)

3. Companion-animal dermatology (Zoetis, Elanco, MSD AH)

4. Veterinary oncology (IDEXX, Zoetis, Elanco)

5. AI diagnostics (IDEXX)

6. Poultry influenza vaccines (Zoetis, Boehringer)

7. Sustainability products such as Bovaer (Elanco)

From a pure R&D portfolio perspective, Zoetis, Elanco and MSD Animal Health currently possess the strongest probability-adjusted pipelines, while Elanco offers the greatest upside if its late-stage assets execute successfully between 2027 and 2031.

Strategic Scorecard Summary